CBDG (THC Farmaceuticals) Equity-to-Asset: 0.45 (As of Jun. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is THC Farmaceuticals Equity-to-Asset?

THC Farmaceuticals CBDG -67.74% Equity-to-Asset is 0.45 as of Jun. 2018.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. THC Farmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2018 was $0.78 Mil. THC Farmaceuticals's Total Assets for the quarter that ended in Jun. 2018 was $1.75 Mil. Therefore, THC Farmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2018 was 0.45.

The historical rank and industry rank for THC Farmaceuticals's Equity-to-Asset or its related term are showing as below:

CBDG's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Equity-to-Asset only.

THC Farmaceuticals  (OTCPK:CBDG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

THC Farmaceuticals Equity-to-Asset Related Terms

THC Farmaceuticals Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for THC Farmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

THC Farmaceuticals Equity-to-Asset Chart

THC Farmaceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13
Equity-to-Asset
0.65 0.70 0.14 -0.35

THC Farmaceuticals Quarterly Data
Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Mar17 Jun17 Mar18 Jun18
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.00 0.00 0.45 0.45

CBDG vs BOXS: Equity-to-Asset Comparison

For the Biotechnology subindustry, THC Farmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

THC Farmaceuticals Equity-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, THC Farmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where THC Farmaceuticals's Equity-to-Asset falls into.


THC Farmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

THC Farmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Sep. 2013 is calculated as

Equity to Asset (A: Sep. 2013 )=Total Stockholders Equity/Total Assets
=-0.017/0.049
=-0.35

THC Farmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2018 is calculated as

Equity to Asset (Q: Jun. 2018 )=Total Stockholders Equity/Total Assets
=0.784/1.751
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of 0.45 mean?
THC Farmaceuticals (CBDG) has a Equity-to-Asset of 0.45 as of Jun. 2018. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on THC Farmaceuticals and its competitors.
Is THC Farmaceuticals' Equity-to-Asset too high?
THC Farmaceuticals' current Equity-to-Asset is 0.45. The Biotechnology industry median Equity-to-Asset is 0.68. THC Farmaceuticals' value of 0.45 is 33.8% below this industry median.
How does THC Farmaceuticals' Equity-to-Asset compare to BOXS?
THC Farmaceuticals' Equity-to-Asset of 0.45 can be compared against companies in the Biotechnology industry. The industry median Equity-to-Asset is 0.68. THC Farmaceuticals' value of 0.45 is 33.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. THC Farmaceuticals's current Equity-to-Asset of 0.45 is 33.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on THC Farmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. THC Farmaceuticals's current Equity-to-Asset is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THC Farmaceuticals stock overvalued right now?
THC Farmaceuticals (CBDG) has a current Equity-to-Asset of 0.45. The current Equity-to-Asset is 0.45 and 33.8% below the Biotechnology industry median of 0.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For THC Farmaceuticals (CBDG), the current Equity-to-Asset is 0.45 as of Jun. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THC Farmaceuticals Business Description

Address 2789 Rio Vista Drive, Suite 3, Saint George, UT, USA, 84790
THC Farmaceuticals Inc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology, and other medical disciplines. It offers the combination of proprietary developments with the expertise of clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds.